{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:43:30Z","timestamp":1780098210743,"version":"3.54.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11899-017-0367-0","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T07:12:08Z","timestamp":1489561928000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["POEMS Syndrome: an Enigma"],"prefix":"10.1007","volume":"12","author":[{"given":"Rahma","family":"Warsame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Yanamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"issue":"4996","key":"367_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/bmj.2.4996.802","volume":"2","author":"RS Crow","year":"1956","unstructured":"Crow RS. Peripheral neuritis in myelomatosis. Br Med J. 1956;2(4996):802\u20134.","journal-title":"Br Med J"},{"issue":"3","key":"367_CR2","first-page":"543","volume":"13","author":"K Takatsuki","year":"1983","unstructured":"Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol. 1983;13(3):543\u201355.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"367_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00005792-198007000-00006","volume":"59","author":"PA Bardwick","year":"1980","unstructured":"Bardwick PA et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore). 1980;59(4):311\u201322.","journal-title":"Medicine (Baltimore)"},{"key":"367_CR4","first-page":"293","volume":"142","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A. Castleman disease. Cancer Treat Res. 2008;142:293\u2013330.","journal-title":"Cancer Treat Res"},{"issue":"6","key":"367_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.34.6.712","volume":"34","author":"T Nakanishi","year":"1984","unstructured":"Nakanishi T et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984;34(6):712\u201320.","journal-title":"Neurology"},{"issue":"7","key":"367_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","volume":"101","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496\u2013506.","journal-title":"Blood"},{"issue":"6","key":"367_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/0002-9343(94)90350-6","volume":"97","author":"MJ Soubrier","year":"1994","unstructured":"Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med. 1994;97(6):543\u201353.","journal-title":"Am J Med"},{"issue":"10","key":"367_CR8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1080\/1042819031000111044","volume":"44","author":"D Singh","year":"2003","unstructured":"Singh D et al. POEMS syndrome: experience with fourteen cases. Leuk Lymphoma. 2003;44(10):1749\u201352.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"367_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00277-010-1149-0","volume":"90","author":"J Li","year":"2011","unstructured":"Li J et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol. 2011;90(7):819\u201326.","journal-title":"Ann Hematol"},{"issue":"11","key":"367_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(16)30176-4","volume":"15","author":"A Jaccard","year":"2016","unstructured":"Jaccard A, Magy L. Thalidomide and POEMS syndrome: a cautious step forward. Lancet Neurol. 2016;15(11):1104\u20135.","journal-title":"Lancet Neurol"},{"key":"367_CR11","unstructured":"Fermand JP. From monoclonal gammopathy of undetermined significance (MGUS) to monoclonal gammopathy of clinical significance. In: World Congress on controversies in multiple myeloma. Paris, France; 2016."},{"issue":"10","key":"367_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.24171","volume":"90","author":"A Dispenzieri","year":"2015","unstructured":"Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90(10):951\u201362.","journal-title":"Am J Hematol"},{"issue":"12","key":"367_CR13","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1182\/blood-2005-12-5045","volume":"107","author":"O Straume","year":"2006","unstructured":"Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood. 2006;107(12):4972\u20133. author reply 4973-4.","journal-title":"Blood"},{"issue":"3","key":"367_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood-2005-03-0910","volume":"106","author":"A Badros","year":"2005","unstructured":"Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood. 2005;106(3):1135.","journal-title":"Blood"},{"issue":"6","key":"367_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1212\/WNL.0b013e318263c42b","volume":"79","author":"K Kanai","year":"2012","unstructured":"Kanai K et al. Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology. 2012;79(6):575\u201382.","journal-title":"Neurology"},{"issue":"9002","key":"367_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(96)91261-1","volume":"347","author":"O Watanabe","year":"1996","unstructured":"Watanabe O et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347(9002):702.","journal-title":"Lancet"},{"issue":"3","key":"367_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2007-12-126979","volume":"112","author":"D Abe","year":"2008","unstructured":"Abe D et al. Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood. 2008;112(3):836\u20139.","journal-title":"Blood"},{"key":"367_CR18","doi-asserted-by":"crossref","unstructured":"Mangalik A, Veliath AJ. Osteosclerotic myeloma with polyneuropathy. A case report. Cancer. 1971;28:1040\u20135.","DOI":"10.1002\/1097-0142(1971)28:4<1040::AID-CNCR2820280430>3.0.CO;2-A"},{"issue":"2","key":"367_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejrad.2009.06.004","volume":"76","author":"MA Alberti","year":"2010","unstructured":"Alberti MA et al. 18F-FDG PET\/CT in the evaluation of POEMS syndrome. Eur J Radiol. 2010;76(2):180\u20132.","journal-title":"Eur J Radiol"},{"issue":"1","key":"367_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0284185114564614","volume":"57","author":"X Shi","year":"2016","unstructured":"Shi X et al. CT characteristics in 24 patients with POEMS syndrome. Acta Radiol. 2016;57(1):51\u20137.","journal-title":"Acta Radiol"},{"issue":"1","key":"367_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","volume":"120","author":"A D\u2019Souza","year":"2012","unstructured":"D\u2019Souza A et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120(1):56\u201362.","journal-title":"Blood"},{"issue":"11","key":"367_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.wnl.0000344569.13496.ff","volume":"72","author":"E Nobile-Orazio","year":"2009","unstructured":"Nobile-Orazio E et al. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology. 2009;72(11):1024\u20136.","journal-title":"Neurology"},{"issue":"24","key":"367_CR23","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2010-11-316935","volume":"117","author":"LN Dao","year":"2011","unstructured":"Dao LN et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood. 2011;117(24):6438\u201344.","journal-title":"Blood"},{"issue":"17","key":"367_CR24","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","volume":"118","author":"A D\u2019Souza","year":"2011","unstructured":"D\u2019Souza A et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118(17):4663\u20135.","journal-title":"Blood"},{"issue":"16","key":"367_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/WNL.0b013e3181bd136b","volume":"73","author":"SA Dupont","year":"2009","unstructured":"Dupont SA et al. Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology. 2009;73(16):1308\u201312.","journal-title":"Neurology"},{"issue":"6","key":"367_CR26","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.3324\/haematol.2013.102962","volume":"99","author":"C Wang","year":"2014","unstructured":"Wang C et al. Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow up of patients with POEMS syndrome. Haematologica. 2014;99(6):e78\u201380.","journal-title":"Haematologica"},{"issue":"11","key":"367_CR27","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1182\/blood.V93.11.3643.411k38_3643_3653","volume":"93","author":"L Belec","year":"1999","unstructured":"Belec L et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman\u2019s disease. Blood. 1999;93(11):3643\u201353.","journal-title":"Blood"},{"issue":"1","key":"367_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/1097-0142(19850701)56:1<188::AID-CNCR2820560132>3.0.CO;2-Z","volume":"56","author":"MA Bitter","year":"1985","unstructured":"Bitter MA, Komaiko W, Franklin WA. Giant lymph node hyperplasia with osteoblastic bone lesions and the POEMS (Takatsuki\u2019s) syndrome. Cancer. 1985;56(1):188\u201394.","journal-title":"Cancer"},{"issue":"3","key":"367_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/ajcp\/105.3.268","volume":"105","author":"DM Menke","year":"1996","unstructured":"Menke DM et al. Diagnosis of Castleman\u2019s disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105(3):268\u201376.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"367_CR30","first-page":"525","volume":"5","author":"DM Menke","year":"1992","unstructured":"Menke DM, Camoriano JK, Banks PM. Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol. 1992;5(5):525\u201330.","journal-title":"Mod Pathol"},{"issue":"3","key":"367_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jocn.2010.07.124","volume":"18","author":"GB Kulkarni","year":"2011","unstructured":"Kulkarni GB et al. Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome. J Clin Neurosci. 2011;18(3):356\u201360.","journal-title":"J Clin Neurosci"},{"issue":"2-3","key":"367_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0022-510X(89)90027-0","volume":"89","author":"M Donaghy","year":"1989","unstructured":"Donaghy M et al. Peripheral neuropathy associated with Castleman\u2019s disease. J Neurol Sci. 1989;89(2-3):253\u201367.","journal-title":"J Neurol Sci"},{"issue":"Pt 8","key":"367_CR33","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/brain\/awh519","volume":"128","author":"M Scarlato","year":"2005","unstructured":"Scarlato M et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128(Pt 8):1911\u201320.","journal-title":"Brain"},{"issue":"5","key":"367_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp-2011-301706","volume":"83","author":"S Nasu","year":"2012","unstructured":"Nasu S et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012;83(5):476\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"367_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/jnnp-2011-301472","volume":"83","author":"ML Mauermann","year":"2012","unstructured":"Mauermann ML et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry. 2012;83(5):480\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"367_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/mus.24768","volume":"52","author":"E Naddaf","year":"2015","unstructured":"Naddaf E et al. Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2015;52(4):658\u20139.","journal-title":"Muscle Nerve"},{"issue":"10 Pt 1","key":"367_CR37","first-page":"979","volume":"158","author":"E Nobile-Orazio","year":"2002","unstructured":"Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris). 2002;158(10 Pt 1):979\u201387.","journal-title":"Rev Neurol (Paris)"},{"key":"367_CR38","doi-asserted-by":"publisher","unstructured":"Kapoor PAS, Fonseca R, et. al. Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncology. 2017 Published online January 5, 2017. doi:10.1001\/jamaoncol.2016.5763.","DOI":"10.1001\/jamaoncol.2016.5763"},{"issue":"24","key":"367_CR39","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1182\/blood-2011-03-342675","volume":"117","author":"A Dispenzieri","year":"2011","unstructured":"Dispenzieri A. Ushering in a new era for POEMS. Blood. 2011;117(24):6405\u20136.","journal-title":"Blood"},{"issue":"6","key":"367_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ajh.24356","volume":"91","author":"TV Kourelis","year":"2016","unstructured":"Kourelis TV et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. Am J Hematol. 2016;91(6):585\u20139.","journal-title":"Am J Hematol"},{"issue":"5","key":"367_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/leu.2015.344","volume":"30","author":"TV Kourelis","year":"2016","unstructured":"Kourelis TV et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30(5):1079\u201385.","journal-title":"Leukemia"},{"key":"367_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13014-014-0265-8","volume":"9","author":"YG Suh","year":"2014","unstructured":"Suh YG et al. The role of radiotherapy in the management of POEMS syndrome. Radiat Oncol. 2014;9:265.","journal-title":"Radiat Oncol"},{"issue":"1","key":"367_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","volume":"122","author":"MS Humeniuk","year":"2013","unstructured":"Humeniuk MS et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013;122(1):68\u201373.","journal-title":"Blood"},{"issue":"1","key":"367_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1212\/01.wnl.0000188757.38495.23","volume":"66","author":"S Kuwabara","year":"2006","unstructured":"Kuwabara S et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66(1):105\u20137.","journal-title":"Neurology"},{"issue":"6","key":"367_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archdermatol.2010.100","volume":"146","author":"S Barete","year":"2010","unstructured":"Barete S et al. Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol. 2010;146(6):615\u201323.","journal-title":"Arch Dermatol"},{"issue":"1","key":"367_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.bmt.1703600","volume":"30","author":"M Soubrier","year":"2002","unstructured":"Soubrier M et al. Successful use of autologous bone marrow transplantation in treating a patient with POEMS syndrome. Bone Marrow Transplant. 2002;30(1):61\u20132.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"367_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","volume":"80","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008;80(5):397\u2013406.","journal-title":"Eur J Haematol"},{"issue":"24","key":"367_CR48","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1182\/blood-2010-12-328112","volume":"117","author":"J Li","year":"2011","unstructured":"Li J et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011;117(24):6445\u20139.","journal-title":"Blood"},{"issue":"4","key":"367_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.12492","volume":"95","author":"QQ Cai","year":"2015","unstructured":"Cai QQ et al. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. Eur J Haematol. 2015;95(4):325\u201330.","journal-title":"Eur J Haematol"},{"issue":"11","key":"367_CR50","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1474-4422(16)30157-0","volume":"15","author":"S Misawa","year":"2016","unstructured":"Misawa S et al. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(11):1129\u201337.","journal-title":"Lancet Neurol"},{"issue":"6","key":"367_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ajh.23195","volume":"87","author":"B Vannata","year":"2012","unstructured":"Vannata B et al. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. Am J Hematol. 2012;87(6):641\u20132.","journal-title":"Am J Hematol"},{"issue":"3","key":"367_CR52","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1182\/blood-2007-03-082354","volume":"110","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood. 2007;110(3):1075\u20136.","journal-title":"Blood"},{"issue":"21","key":"367_CR53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V124.21.36.36","volume":"124","author":"A Jaccard","year":"2014","unstructured":"Jaccard A et al. A prospective phase II trial of lenalidomide and dexamethasone (LEN-DEX) in POEMS syndrome. Blood. 2014;124(21):36.","journal-title":"Blood"},{"issue":"3","key":"367_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/ajh.23374","volume":"88","author":"B Royer","year":"2013","unstructured":"Royer B et al. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol. 2013;88(3):207\u201312.","journal-title":"Am J Hematol"},{"issue":"9","key":"367_CR55","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3109\/10428194.2013.869329","volume":"55","author":"F Zagouri","year":"2014","unstructured":"Zagouri F et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma. 2014;55(9):2018\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"367_CR56","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1053\/j.ajkd.2006.01.004","volume":"47","author":"S Sanada","year":"2006","unstructured":"Sanada S et al. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. Am J Kidney Dis. 2006;47(4):672\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"367_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajh.20280","volume":"79","author":"AK Ganti","year":"2005","unstructured":"Ganti AK et al. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005;79(3):206\u201310.","journal-title":"Am J Hematol"},{"issue":"6","key":"367_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bmt.1703670","volume":"30","author":"KS Peggs","year":"2002","unstructured":"Peggs KS et al. Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplant. 2002;30(6):401\u20134.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"367_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.bmt.1703108","volume":"28","author":"WJ Hogan","year":"2001","unstructured":"Hogan WJ et al. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2001;28(3):305\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"367_CR60","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1182\/blood-2012-03-378992","volume":"119","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A. How I treat POEMS syndrome. Blood. 2012;119(24):5650\u20138.","journal-title":"Blood"},{"issue":"2","key":"367_CR61","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1532\/IJH97.06067","volume":"84","author":"H Kojima","year":"2006","unstructured":"Kojima H et al. Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue. Int J Hematol. 2006;84(2):182\u20135.","journal-title":"Int J Hematol"},{"issue":"8998","key":"367_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347(8998):353\u20137.","journal-title":"Lancet"},{"issue":"5","key":"367_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.nmd.2009.02.004","volume":"19","author":"N Imai","year":"2009","unstructured":"Imai N et al. Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation. Neuromuscul Disord. 2009;19(5):363\u20135.","journal-title":"Neuromuscul Disord"},{"key":"367_CR64","first-page":"CD006828","volume":"6","author":"S Kuwabara","year":"2012","unstructured":"Kuwabara S et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6:CD006828.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"367_CR65","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp.63.3.385","volume":"63","author":"S Kuwabara","year":"1997","unstructured":"Kuwabara S et al. Long term melphalan-prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry. 1997;63(3):385\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"367_CR66","first-page":"348","volume":"20","author":"JW Zhou","year":"2012","unstructured":"Zhou JW et al. Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome). Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(2):348\u201351.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"367_CR67","doi-asserted-by":"publisher","first-page":"e007330","DOI":"10.1136\/bmjopen-2014-007330","volume":"5","author":"K Katayama","year":"2015","unstructured":"Katayama K et al. Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II\/III multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open. 2015;5(1):e007330.","journal-title":"BMJ Open"},{"issue":"1","key":"367_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","volume":"66","author":"AM Roccaro","year":"2006","unstructured":"Roccaro AM et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66(1):184\u201391.","journal-title":"Cancer Res"},{"issue":"6","key":"367_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1600-0609.2012.01780.x","volume":"88","author":"R Warsame","year":"2012","unstructured":"Warsame R, Kohut IE, Dispenzieri A. Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. Eur J Haematol. 2012;88(6):549\u201350.","journal-title":"Eur J Haematol"},{"issue":"6","key":"367_CR70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1600-0609.2009.01330.x","volume":"83","author":"X Tang","year":"2009","unstructured":"Tang X et al. Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol. 2009;83(6):609\u201310.","journal-title":"Eur J Haematol"},{"issue":"2","key":"367_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000343681","volume":"129","author":"K Zeng","year":"2013","unstructured":"Zeng K et al. Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature. Acta Haematol. 2013;129(2):101\u20135.","journal-title":"Acta Haematol"},{"issue":"12","key":"367_CR72","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3109\/10428194.2012.690515","volume":"53","author":"J Li","year":"2012","unstructured":"Li J et al. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leuk Lymphoma. 2012;53(12):2527\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"367_CR73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00277-010-1133-8","volume":"90","author":"H Ohguchi","year":"2011","unstructured":"Ohguchi H et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Ann Hematol. 2011;90(9):1113\u20134.","journal-title":"Ann Hematol"},{"issue":"2","key":"367_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-0609.2009.01341.x","volume":"84","author":"I Kaygusuz","year":"2010","unstructured":"Kaygusuz I et al. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol. 2010;84(2):175\u20137.","journal-title":"Eur J Haematol"},{"issue":"10","key":"367_CR75","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jjco\/hyr120","volume":"41","author":"X Wang","year":"2011","unstructured":"Wang X et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman\u2019s disease. Jpn J Clin Oncol. 2011;41(10):1221\u20134.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"367_CR76","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3341\/kjo.2015.29.5.354","volume":"29","author":"W Kim do","year":"2015","unstructured":"Kim do W et al. Intravitreal bevacizumab for the treatment of optic disc edema in a patient with POEMS syndrome. Korean J Ophthalmol. 2015;29(5):354\u20136.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"367_CR77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/annonc\/mdm602","volume":"19","author":"PY Dietrich","year":"2008","unstructured":"Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol. 2008;19(3):595.","journal-title":"Ann Oncol"},{"issue":"12","key":"367_CR78","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/jnnp-2012-304874","volume":"84","author":"Y Sekiguchi","year":"2013","unstructured":"Sekiguchi Y et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013;84(12):1346\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"367_CR79","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3341\/kjo.2015.29.5.357","volume":"29","author":"HB Song","year":"2015","unstructured":"Song HB, Yu HG. Optic disc edema responding to localized anti-vascular endothelial growth factor treatment in a patient with POEMS syndrome. Korean J Ophthalmol. 2015;29(5):357\u20138.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"367_CR80","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.21718","volume":"42","author":"C Terracciano","year":"2010","unstructured":"Terracciano C et al. Inverse correlation between VEGF and soluble VEGF receptor 2 in POEMS with AIDP responsive to intravenous immunoglobulin. Muscle Nerve. 2010;42(3):445\u20138.","journal-title":"Muscle Nerve"},{"issue":"6","key":"367_CR81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.blre.2007.07.004","volume":"21","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A. POEMS syndrome. Blood Rev. 2007;21(6):285\u201399.","journal-title":"Blood Rev"},{"issue":"8","key":"367_CR82","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/art.1780390824","volume":"39","author":"FJ Authier","year":"1996","unstructured":"Authier FJ et al. All-trans-retinoic acid in POEMS syndrome. Therapeutic effect associated with decreased circulating levels of proinflammatory cytokines. Arthritis Rheum. 1996;39(8):1423\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"367_CR83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/cei.12755","volume":"184","author":"L Ma","year":"2016","unstructured":"Ma L et al. Autologous cytokine-induced killer (CIK) cell immunotherapy combined with cyclophosphamide in five patients with POEMS syndrome. Clin Exp Immunol. 2016;184(1):83\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"367_CR84","first-page":"158","volume":"18","author":"DR Guay","year":"2003","unstructured":"Guay DR. Update on gabapentin therapy of neuropathic pain. Consult Pharm. 2003;18(2):158\u201370. 173-8.","journal-title":"Consult Pharm"},{"issue":"12","key":"367_CR85","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.3109\/10428194.2014.893309","volume":"55","author":"L Zhang","year":"2014","unstructured":"Zhang L et al. Prevalence and risk factors for depression in newly diagnosed patients with POEMS syndrome. Leuk Lymphoma. 2014;55(12):2835\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"367_CR86","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/leu.2016.168","volume":"31","author":"C Wang","year":"2016","unstructured":"Wang C et al. Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia. 2016;31(1):100\u20136.","journal-title":"Leukemia"},{"issue":"1","key":"367_CR87","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ejh.12682","volume":"97","author":"C Wang","year":"2016","unstructured":"Wang C et al. Prognostic value of serum heavy\/light chain ratios in patients with POEMS syndrome. Eur J Haematol. 2016;97(1):48\u201354.","journal-title":"Eur J Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-017-0367-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:02:08Z","timestamp":1659088928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-017-0367-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0367-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]},"assertion":[{"value":"15 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rahma Warsame and Uday Yanamandra each declare no potential conflicts of interest. Prashant Kapoor reports grants from Amgen, Takeda, and Celgene. Dr. Kapoor is a section editor for <i>Current Hematologic Malignancy Reports<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}